In Situ Antigen Modification-Based Target-Redirected Universal Chimeric Antigen Receptor T (TRUE CAR-T) Cell Therapy in Solid Tumors

Investigator established a target-redirected universal CAR-T cell therapeutic modality, in which exogenous antigens were loaded onto fusogenic nanoparticles to achieve in situ modification of cell membrane in solid tumors, providing targets for subsequent CAR-T cell therapy.